The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease
Abstract
OBJECTIVE: To investigate the effect of different antithyroid drug (ATD) regimens on relapse rates of Graves' disease, and to look for predictors of relapse. DESIGN AND METHODS: In a prospective two-way factorial randomized clinical trial, 218 patients with Graves' disease were assigned to ATD combined with l-thyroxine (l-T(4)) or ATD alone for 12 Months. After discontinuation of antithyroid therapy, each group was stratified to either 12 Months further treatment with l-T(4) or no treatment. Clinical and biochemical assessments were carried out before treatment, after 3 and 6 weeks, and every third Month for 12 Months. If the patients lacked symptoms of relapse, laboratory tests were performed every third Month for the second Year, and thereafter annually. RESULTS: The proportion of all patients with relapse was 47.7% 2 Years after withdrawal of ATD. There was no difference in relapse rates between the treatment groups (P=0.217, log--rank test). Smokers had a higher relapse rate than non-smokers (58.4% vs 38.8%, P=0.009). Patients who were thyrotropin-receptor antibody (TRAb) positive after 12 Months of antithyroid therapy had a higher relapse rate than those who were negative (72.5% vs 36.8%, P<0.0001). Similarly, relapse was more frequent (55.5%) in patients having large goiter compared with subjects with small goiter (36.3%, P=0.0007). CONCLUSIONS: Relapse rates of Graves' disease were independent of ATD regimen whether followed by l-T(4) therapy or not. Smoking, large goiter and presence of TRAb at the end of ATD therapy were strong predictors of relapse.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A lower remission rate has been described in men, smokers (especially men), and those with large goiters ( ‡80 g) (165-169).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [167]
In the citing paper
“In patients with negative TRAb, relapses tend to occur relatively later than those that develop in patients whose MMI is stopped when TRAb is still positive (171,176), although 5% occurred within the first 2 months in one study (167).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [167]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Autoimmune Thyroid Disease: Further Developments in Our Understanding*
Weetman, A. P., & McGregor, A. M. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-6-788 · Cited by 656
Smoking and thyroid disorders--a meta-analysis
Vestergaard, P. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460153 · Cited by 308
VITTI, P., RAGO, T., CHIOVATO, L., PALLINI, S., SANTINI, F., FIORE, E., ROCCHI, R., MARTINO, E., & PINCHERA, A. (1997) · Thyroid · doi:10.1089/thy.1997.7.369 · Cited by 293
Age and Gender Predict the Outcome of Treatment for Graves' Hyperthyroidism
Allahabadia, A., Daykin, J., HOLDER, R. L., Sheppard, M. C., Gough, S. C. L., & Franklyn, J. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6430 · Cited by 286
Administration of Thyroxine in Treated Graves' Disease
Hashizume, K., Ichikawa, K., Sakurai, A., Suzuki, S., Takeda, T., Kobayashi, M., Miyamoto, T., Arai, M., & Nagasawa, T. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104043241403 · Cited by 214
Allannic, H., Fauchet, R., Orgiazzi, J., Orgiazzi, A., GENETET, B., LORCY, Y., GUERRIER, A. M. L., Delambre, C., & Derennes, V. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-3-675 · Cited by 192
Feldt‐Rasmussen, U., Schleusener, H., & Carayon, P. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.1.8288723 · Cited by 184
Cited by
Sorted by citations
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
“Based on the latter studies, the risk of relapse of hyperthyroidism within a 2-month interval after ATD withdrawal in TRAb-negative nonsmoking patients who have already been treated for 12–24 months is <10% (167,475).”
BackgroundStagnaro-Green, A., Abalovich, M., Alexander, E., Azizi, F., Mestman, J., Negro, R., Nixon, A., Pearce, E. N., Soldin, O. P., Sullivan, S., et al. (2011) · Thyroid · doi:10.1089/thy.2011.0087 · Cited by 2,942
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731
Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.456 · Cited by 1,098
Cooper, D. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmra042972 · Cited by 1,008
2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K. G., & Pearce, S. H. S. (2018) · European Thyroid Journal · doi:10.1159/000490384 · Cited by 1,025
The American Thyroid Association and American Association of Clinical Endocrinologists Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis, Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0417 · Cited by 898
Thyroid disease in pregnancy: new insights in diagnosis and clinical management
Korevaar, T. I. M., Medici, M., Visser, T. J., & Peeters, R. P. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.93 · Cited by 441
Wiersinga, W. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12222 · Cited by 389
Diagnosis and management of Graves disease: a global overview
Bartalena, L. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.193 · Cited by 311
Franklyn, J. A., & Boelaert, K. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60782-4 · Cited by 262
Antithyroid drug regimen for treating Graves’ hyperthyroidism
Abraham, P., Avenell, A., McGeoch, S. C., Clark, L. F., & Bevan, J. S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003420.pub4 · Cited by 249
Smoke and autoimmunity: The fire behind the disease
Perricone, C., Versini, M., Ben-Ami, D., Gertel, S., Watad, ., Segel, M., Ceccarelli, F., Conti, F., Cantarini, L., Bogdanos, D. P., et al. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.01.001 · Cited by 248
A systematic review of drug therapy for Graves’ hyperthyroidism
Abraham, P., Avenell, A., Park, C. M., Watson, W. A., & Bevan, J. S. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01993 · Cited by 211
Vos, X. G., Endert, E., Zwinderman, A. H., Tijssen, J. G. P., & Wiersinga, W. M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3644 · Cited by 190
Kaguelidou, F., Alberti, C., Castanet, M., Guitteny, M.-A., Czernichow, P., & Léger, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0842 · Cited by 173
Cooper, D. (2003) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2003-030185 · Cited by 142
Hyperthyroidism: diagnosis and treatment.
Reid, J., & Wheeler, S. F. (2005) · PubMed · Cited by 140
Epidemiology, management and outcomes of Graves’ disease—real life data
Hussain, Y. S., Hookham, J., Allahabadia, A., & Balasubramanian, S. P. (2017) · Endocrine · doi:10.1007/s12020-017-1306-5 · Cited by 118
Long-Term Antithyroid Drug Treatment: A Systematic Review and Meta-Analysis
Azizi, F., & Malboosbaf, R. (2017) · Thyroid · doi:10.1089/thy.2016.0652 · Cited by 114
The Long-Term Outcome of Treatment for Graves' Hyperthyroidism
Sjölin, G., Holmberg, M., Törring, O., Byström, K., Khamisi, S., de Laval, D., Abraham‐Nordling, M., Calissendorff, J., Lantz, M., Hallengren, B., et al. (2019) · Thyroid · doi:10.1089/thy.2019.0085 · Cited by 112
Mazza, E., Carlini, M., Flecchia, D., Blatto, A., Zuccarini, O., Gamba, S., Beninati, S., & Messina, M. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346433 · Cited by 88
Laurberg, P., Berman, D. C., Andersen, S., & Pedersen, I. B. (2011) · Thyroid · doi:10.1089/thy.2011.0039 · Cited by 87
Hyperthyroidism in Childhood: Causes, when and how to treat
Léger, J., & Carel, J. (2012) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.854 · Cited by 83
Smoking and autoimmune thyroid disease: the plot thickens
Krassas, G. E., & Wiersinga, W. M. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02157 · Cited by 83
Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease
Kahaly, G. J., Diana, T., Kanitz, M., Frommer, L., & Olivo, P. D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz292 · Cited by 82
Quadbeck, B., Hoermann, R., Roggenbuck, U., Hahn, S., Mann, K., & Janssen, O. E. (2005) · Thyroid · doi:10.1089/thy.2005.15.1047 · Cited by 79
Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis
Corpechot, C., Gaouar, F., Chrétien, Y., Johanet, C., Chazouillères, O., & Poupon, R. Y. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.031 · Cited by 75
Thyrotropin Receptor Antibodies—An Overview
Kotwal, A., & Stan, M. N. (2018) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000001052 · Cited by 73
Bartalena, L., Chiovato, L., & Vitti, P. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0505-x · Cited by 75
Graves’ Disease in Childhood: Advances in Management with Antithyroid Drug Therapy
Kaguelidou, F., Carel, J., & Léger, J. (2009) · Hormone Research in Paediatrics · doi:10.1159/000223414 · Cited by 71
Mohlin, E., Nyström, H. F., & Eliasson, M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0811 · Cited by 69
Léger, J., Kaguelidou, F., Alberti, C., & Carel, J. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.08.008 · Cited by 65
Relapse following antithyroid drug therapy for Graves’ hyperthyroidism
Laurberg, P., Krejbjerg, A., & Andersen, S. L. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000088 · Cited by 60
Diagnosis and management of hyperthyroidism from prenatal life to adolescence
Léger, J., & Carel, J. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.03.014 · Cited by 57
Current and emerging treatment options for Graves’ hyperthyroidism
Abraham, P., & Acharya (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5229 · Cited by 57
Kobaly, K. N., & Mandel, S. J. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.05.002 · Cited by 53
Outcome Prediction of Treatment of Graves’ Hyperthyroidism with Antithyroid Drugs
Piantanida, E., Lai, A., Sassi, L., Gallo, D., Spreafico, E., Tanda, M. L., & Bartalena, L. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1555759 · Cited by 53
The safety and efficacy of antithyroid drugs
Azizi, F. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.1.107 · Cited by 52
Antithyroid drug regimen for treating Graves' hyperthyroidism
Abraham, P., Avenell, A., Watson, W. A., Park, C. M., & Bevan, J. S. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003420.pub3 · Cited by 50
Razvi, S., Vaidya, B., Perros, P., & Pearce, S. H. S. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02169 · Cited by 47
Graves' disease in children and adolescents: Response to long‐term treatment
Barrio, R., López-Capapé, M., Martínez-Badás, I., Carrillo, Á., Moreno, J. C., & Alonso, M. (2005) · Acta Paediatrica · doi:10.1080/08035250500252872 · Cited by 42
Thyroid Disease in Pregnancy: A Descriptive Review of Guidelines
Tsakiridis, I. G., Giouleka, S., Kourtis, A., Mamopoulos, A. M., Athanasiadis, A. P., & Dagklis, T. (2022) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000960 · Cited by 43
Kawkgi, O. M. E., Ross, D. S., & Stan, M. N. (2020) · Clinical Endocrinology · doi:10.1111/cen.14374 · Cited by 46
Mao, X., Li, H., Li, Q., Li, D. M., Xie, X., Yin, G., Zhang, P., Xu, X., Wu, J.-D., Chen, S.-W., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1252 · Cited by 33
Function of regulatory T-cells improved by dexamethasone in Graves' disease
Hu, Y., Tian, W., Zhang, L., Liu, H., Yin, G., He, B., & Mao, X. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0879 · Cited by 33
The Diagnosis and Management of Hyperthyroidism Consensus - Report of the Korean Thyroid Association
Yi, K. H., Moon, J. H., Kim, I.-J., Bom, H.-S., Lee, J., Chung, W. Y., Chung, J. H., & Shong, Y. K. (2013) · Journal of Korean Thyroid Association · doi:10.11106/jkta.2013.6.1.1 · Cited by 32
Kim, Y. A., Cho, S. W., Choi, H. S., Moon, S., Moon, J. H., Kim, K. W., Park, D. J., Yi, K. H., Park, Y. J., & Cho, B. Y. (2016) · Thyroid · doi:10.1089/thy.2016.0056 · Cited by 32
Management of thyroid disorders
Premawardhana, L. D. K. E., & Lazarus, J. H. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.047290 · Cited by 34
Evaluating thyroid function in pregnant women
Geno, K. A., & Nerenz, R. D. (2022) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2022.2050182 · Cited by 31
Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy
Stokland, A. M., Austdal, M., Nedrebø, B. G., Carlsen, S., Hetland, H. B., Breivik, L., Ueland, H. O., Watt, T., Cramon, P. K., Løvås, K., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad538 · Cited by 28
Self-citationManagement of Thyrotoxicosis: Preconception, Pregnancy, and the Postpartum Period
Pearce, E. N. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0356 · Cited by 26
Serum 25-hydroxyvitamin D might be an independent prognostic factor for Graves disease recurrence
Ahn, H. Y., Chung, Y. J., & Cho, B. Y. (2017) · Medicine · doi:10.1097/md.0000000000007700 · Cited by 24
Park, S., Song, E., Oh, H., Kim, M., Jeon, M. J., Kim, W. G., Kim, T. Y., Shong, Y. K., Kim, D. M., & Kim, W. B. (2019) · Endocrine · doi:10.1007/s12020-019-01987-w · Cited by 24
Management of Thyroid Disorders in Pregnancy
Chan, S., Marsh, M. S., Gilbert, J., Boelaert, K., Evans, C., & Dhillon‐Smith, R. K. (2025) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.18088 · Cited by 31
Karmisholt, J., Andersen, S. L., Pedersen, I. B., Carlé, A., Krejbjerg, A., & Nygaard, B. (2019) · Journal of Thyroid Research · doi:10.1155/2019/5945178 · Cited by 23
Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves’ Disease
Azizi, F., Mehran, L., Abdi, H., & Amouzegar, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae456 · Cited by 24
Independent Pretreatment Predictors of Graves’ Disease Outcome
Daukšienė, D., Daukša, A., & Mickuvienė, N. (2013) · Medicina · doi:10.3390/medicina49100067 · Cited by 21
Long-Term Treatment with Antithyroid Drugs: Efficacy and Safety
Malboosbaf, R., & Azizi, F. (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.101487 · Cited by 24
Hustad, S., Nedrebø, B. G., Ueland, P. M., Schneede, J., Vollset, S. E., Ulvik, A., & Lien, E. A. (2004) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.4.1050 · Cited by 20
Self-citationCurrent trends in antithyroid drug treatment of Graves’ disease
Okosieme, O. E., & Lazarus, J. H. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1232388 · Cited by 19
Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
Alfadda, A. A., Malabu, U. H., EL-DESOUKI, M. I., Al-Rubeaan, K. A., Al-Ruhaily, A. D., Fouda, M. A., Al-Maatouq, M. A., & Sulimani, R. A. (2007) · Saudi Medical Journal · doi:10.15537/1658-3175.3777 · Cited by 19
Autoimmune Thyroid Disorders in Autoimmune Addison Disease
Stokland, A. M., Ueland, G. Å., Lima, K., Grønning, K., Finnes, T. E., Svendsen, M., Tomkowicz, A., Holte, S. E., Sollid, S. T., Dębowska, A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac089 · Cited by 20
Self-citationTreatment of Graves Hyperthyroidism with Thionamides-Derived Drugs: Review
García-Mayor, R. V., & Larrañaga, A. (2010) · Medicinal Chemistry · doi:10.2174/1573406411006040239 · Cited by 18
An update on the pharmacological management of hyperthyroidism due to Graves’ disease
Bartalena, L., Tanda, M. L., Bogazzi, F., Piantanida, E., Lai, A., & Martino, E. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.6.851 · Cited by 17
Kim, M., Kim, B. H., Jang, M. H., Kim, J. M., Kim, E. H., Jeon, Y. K., Kim, S. S., & Kim, I. J. (2019) · Endocrine · doi:10.1007/s12020-019-02137-y · Cited by 17
Valuable predictive features of relapse of Graves’ disease after antithyroid drug treatment
Liu, X., Shi, B., & Li, H. (2015) · Annales d Endocrinologie · doi:10.1016/j.ando.2015.08.004 · Cited by 16
Antithyroid drug therapy of Graves’ hyperthyroidism: realistic goals and focus on evidence
Laurberg, P., Andersen, S., & Karmisholt, J. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.1.91 · Cited by 17
Peng, R., Xie, P., Zhou, J., Zhou, W., Wang, Y., Chen, X., Yin, Q., Shen, L., Meng, L., Ye, L., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae892 · Cited by 15
Nedrebø, B. G., Hustad, S., Schneede, J., Ueland, P. M., Vollset, S. E., Holm, P. I., Aanderud, S., & Lien, E. A. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01222.x · Cited by 14
Self-citationSong, R., Qin, Q., Wang, X., Yan, N., Meng, S., Shi, X., He, S., & Zhang, J. (2015) · Clinical Endocrinology · doi:10.1111/cen.12778 · Cited by 13
Diker‐Cohen, T., Duskin‐Bitan, H., Shimon, I., Hirsch, D., Akirov, A., Tsvetov, G., & Robenshtok, E. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0365 · Cited by 13
Korevaar, T. I. M. (2017) · Thyroid · doi:10.1089/thy.2017.29040.tko · Cited by 13
Ueland, G. Å., Ueland, H. O., Stokland, A. M., Bhan, A., Schønberg, A., Sollid, S. T., Morgas, D. E., Holmøy, T., Lima, K., Methlie, P., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad540 · Cited by 13
Self-citationHwang, S., Shin, D. Y., Song, M. K., & Lee, E. J. (2014) · Endocrine · doi:10.1007/s12020-014-0325-8 · Cited by 12
Katahira, M., & Ogata, H. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.6095 · Cited by 12
Singhal, N., Pavithran, P. V., Bhavani, N., Menon, A. S., Menon, U. V., Abraham, N., Kumar, H., Jaykumar, R. V., Nair, V., Sundaram, S., et al. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.176360 · Cited by 12
Fetal Goitre in Maternal Graves’ Disease
Panaitescu, A. M. (2018) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2018.85 · Cited by 12
Surgical Management of Hyperthyroidism
Al‐Hilli, Z., Cheung, C. X., McDermott, E. W. M., & Prichard, R. S. (2014) · InTech eBooks · doi:10.5772/57499 · Cited by 12
Remission of Grave's disease after oral anti-thyroid drug treatment.
Ishtiaq, O., Waseem, S., Haque, M., Islam, N., & Jabbar, A. (2009) · PubMed · Cited by 11
Effect of Addition of Thyroxine in the Treatment of Graves’ Disease: A Systematic Review
Li, J., Bai, L., Wei, F., Wei, M., Xiao, Y., Yan, W., & Wei, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.560157 · Cited by 13
Kawkgi, O. M. E., Toro-Tobón, D., Toloza, F. J. K., Vallejo, S., Jacome, C. S., Ayala, I. N., Vallejo, B. A., Wenczenovicz, C., Tzeng, O., Spencer, H. J., et al. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.12.011 · Cited by 9
Katahira, M., Tsunekawa, T., Mizoguchi, A., Yamaguchi, M., Tsuru, K., Takashima, H., & Terada, R. (2023) · HORMONES · doi:10.1007/s42000-023-00437-7 · Cited by 9
Should radioiodine be the first-line treatment for paediatric Graves’ disease?
West, J. D., Cheetham, T. D., Dane, C., & Natarajan, A. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0176 · Cited by 9
Traitement de la maladie de Basedow : problématiques actuelles
Orgiazzi, J. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.09.012 · Cited by 10
Mohamed, T. M., Tousson, E., Beltagy, D. M., & Said, A. S. E. (2014) · Biomedicine and Biotechnology · doi:10.12691/bb-2-4-1 · Cited by 8
Fadeev, V. V. (2020) · Clinical and experimental thyroidology · doi:10.14341/ket12474 · Cited by 9
Hyperthyroidism During Pregnancy: A Clinical Approach
Cuff, R. D. (2019) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000435 · Cited by 9
Bohnet, H. G. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000691 · Cited by 7
Tratamiento del hipertiroidismo por Enfermedad de Graves en pacientes adultos no embarazadas
Ana Fadel, A., Gutiérrez, S., Novelli, J. L., Orlandi, A. M., Parma, R., Croome, M. D. C. S., Chebel, G., Guardia, M., Guido, P., Gilligan, M., et al. (2013) · Revista Argentina de Endocrinología y Metabolismo · Cited by 6
Nouvelles perspectives pour le diagnostic et pronostic de la maladie de Basedow
Tatulashvili, S., Baudry, C., Sadoul, J. L., & Bihan, H. (2018) · Annales d Endocrinologie · doi:10.1016/s0003-4266(18)31239-3 · Cited by 6
The Influence of Juvenile Graves’ Ophthalmopathy on Graves’ Disease Course
Jankauskienė, J., & Jarušaitienė, D. (2017) · Journal of Ophthalmology · doi:10.1155/2017/4853905 · Cited by 6
PROGNOSTIC FACTORS IN THE RELAPSE OF GRAVES DISEASE FOLLOWING TREATMENT WITH ANTITHYROID DRUGS
Soveid, M., Shaabani, A., Ghaedi, G. H., Jafari, S. M., & Omrani, G. R. (2015) · Iranian journal of medical sciences · Cited by 5
Anticorpos anti-tiróide: aspectos metodológicos e importância diagnóstica
Vieira, J. G. H., Kasamatsu, T. S., Hauache, O. M., & Maciel, R. M. B. (2003) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302003000500016 · Cited by 5
Cutovic, M. R., Konstantinović, L. M., Stankovic, Z., & Vesović-Potić, V. (2012) · Disability and Rehabilitation · doi:10.3109/09638288.2012.660599 · Cited by 5
Prediction of Relapse After Antithyroid Drugs Withdrawal: A Narrative Review
Wang, P. (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.102346 · Cited by 6
Giordani, I., & Sykiotis, G. P. (2024) · HORMONES · doi:10.1007/s42000-024-00618-y · Cited by 7
Preconception Counseling and Care for Pregnant Women with Thyroid Disease
Dhillon‐Smith, R. K., & Boelaert, K. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.12.005 · Cited by 4
Antithyroid Drugs for the Treatment of Graves Disease
Peixoto, M. C., Buescu, A., alves, M. R. B. G., Albernaz, M. D. S., Coeli, C. M., & Vaisman, M. (2006) · The Endocrinologist · doi:10.1097/01.ten.0000249137.35809.b3 · Cited by 4
Peixoto, M. C., Buescu, A., Gonçalves, M., Albernaz, M. D. S., Coeli, C. M., & Vaisman, M. (2008) · The Endocrinologist · doi:10.1097/ten.0b013e318165322c · Cited by 3
Metadata
- Authors
- Nedrebo, B., Holm, P., Uhlving, S., Sorheim, J., Skeie, S., Eide, G., Husebye, E., Lien, E., & Aanderud, S.
- Affiliations
- University of Bergen (NO)
- Stord hospital (NO)
- Haukeland University Hospital (NO)
- ORCID
- Skeie, S
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-11-01
- Volume
- 147
- Issue
- 5
- Pages
- 583-589
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2096392089
- Cited by
- 132
- References
- 29
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 5 · 2019: 10 · 2018: 10 · 2017: 7 · 2016: 9 · 2015: 6 · 2014: 8 · 2013: 8 · 2012: 4
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Helse Vest
- Norges Forskningsråd
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- Graves' disease, relapse prevention, antithyroid drugs, levothyroxine, TSH receptor antibodies, smoking, goiter size, predictors of relapse
- MeSH terms
- Antibodies, Drug Combinations, Graves Disease, Humans, Prognosis, Prospective Studies, Receptors, Thyrotropin, Smoking, Antithyroid Agents, Thyroxine, Treatment Outcome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review